[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Dasgupta, 2014 - Google Patents

NORMAL ABL1 IS A TUMOR SUPPRESSOR AND THERAPEUTIC TARGET IN BCR-ABL1-POSITIVE LEUKEMIAS

Dasgupta, 2014

View PDF
Document ID
8913953381455302955
Author
Dasgupta Y
Publication year
Publication venue
Theses and Dissertations

External Links

Snippet

BCR-ABL1 results from t (9; 22)(q34; q11) reciprocal translocation resulting in BCR-ABL1 kinase expression, initiating chronic myeloid leukemia in chronic phase (CML-CP). At the initial stages of CML-CP both oncogenic BCR-ABL1 kinase and normal ABL1 kinase are …
Continue reading at scholarshare.temple.edu (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Similar Documents

Publication Publication Date Title
Asai et al. The p53 tumor suppressor protein regulates hematopoietic stem cell fate
Karvela et al. ATG7 regulates energy metabolism, differentiation and survival of Philadelphia-chromosome-positive cells
Caron et al. Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival
Jin et al. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia
Mondal et al. p53 isoforms regulate aging-and tumor-associated replicative senescence in T lymphocytes
Warsch et al. JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia
Barnes et al. Cytogenetic and molecular genetic aspects of chronic myeloid leukaemia
Chirnomas et al. The inherited bone marrow failure syndromes
Xiong et al. Ribosomal protein S27-like is a physiological regulator of p53 that suppresses genomic instability and tumorigenesis
Ibarra et al. Type I but not type II calreticulin mutations activate the IRE1α/XBP1 pathway of the unfolded protein response to drive myeloproliferative neoplasms
Ingenhag et al. The homeobox transcription factor HB9 induces senescence and blocks differentiation in hematopoietic stem and progenitor cells
Oancea et al. STAT activation status differentiates leukemogenic from non-leukemogenic stem cells in AML and is suppressed by arsenic in t (6; 9)-positive AML
Hee et al. LEE011 and ruxolitinib: a synergistic drug combination for natural killer/T-cell lymphoma (NKTCL)
Mughal et al. Chronic myeloid leukemia: why does it evolve from chronic phase to blast transformation
Cea et al. New insights into biology of chronic myeloid leukemia: implications in therapy
Fredericks et al. The role of RAS effectors in BCR/ABL induced chronic myelogenous leukemia
Dasgupta NORMAL ABL1 IS A TUMOR SUPPRESSOR AND THERAPEUTIC TARGET IN BCR-ABL1-POSITIVE LEUKEMIAS
Miyauchi et al. CAMK2G is identified as a novel therapeutic target for myelofibrosis
Zhang et al. Leukemia stem cells in hematologic malignancies
Liu et al. Endoplasmic reticulum associated degradation preserves hematopoietic stem cell quiescence and self-renewal by restricting mTOR activity
Zhuang Functional role of fatty acid synthase for signal transduction in human acute myeloid leukemia cells
Wei Genome-wide CRISPR/Cas9 Screens Reveal Shared and Bespoke Mechanisms of Resistance to SHP2 inhibition
García Díaz Nuevos mecanismos de tumorogénesis y progresión del linfoma cutáneo de células T: papel de la red de señalización PLCG1-PRKCQ-STAT3
Fleenor Contrasting Roles of C/EBPα and Notch in Ionizing Radiation-induced Multipotent Hematopoietic Progenitor Cell Self-renewal Defects
Retallick IQGAP1 as a Mediator of RAC1 P29S-Driven Melanomagenesis